Reduce Pain and Suffering Caused by Trigger Finger
Raised to Date: Raised: $100,000
Total Commitments ($USD)
Equity - Common
Rolling Commitments ($USD)
That’s where (insert drumroll here please) J-needle comes into play. Using a patent-pending curved needle, the J-needle doesn’t directly pierce the tendon of the inflamed finger. Instead, it enters at an angle, saving both the patient and doctor time, improving accuracy of the medical procedure, and providing the patient with immediate relief. In fact, Jasperate claims that, with the J-needle, doctors can double the amount of trigger fingers treated in a given session. Bam!
Considering that there are 200,000 new cases of trigger finger reported each year, that’s a pretty big deal. Ten percent of diabetics get it, 2-3% of people with it get it randomly. With the population aging and becoming more obese, those numbers (unfortunately) are going to keep rising. In addition to trigger finger, the J-needle can also be used to treat for joint pain, in plastic surgery, neurology, anesthesiology, eye injections...the list goes on. It’s like the superhero of needles.
Founder and Chief Medical Advisor, Dr. Stephen Soloway, has been a doctor for the past 30 years and has earned Top Doctor Awards every year since 2003. The J-needle came out of his experience working with traditional needles and seeing that a change needed to happen. CEO David Weksel and COO Charles Brunner both have extensive leadership experience at companies such as Accenture and SharkNinja, and none of the principal employees will take a salary until revenue is recognized.
J-needles seem to be the only needle of its kind, and with more waistlines expanding and more fingers locking, there is definitely a need for it. Jasperate just might be the pinprick you’ve been looking for to take a stab at a medical investment.
Upgrade to gain access
- Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- , plus
- Company specific
- Advanced company search ( )
- Get Edge Annual
- Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- In-depth risk ratings for every raise
- Get Edge Pro Annual